Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Immunotherapy in Glioblastoma.

TitleImmunotherapy in Glioblastoma.
Publication TypeJournal Article
Year of Publication2018
AuthorsWilcox JA, Ramakrishna R, Magge R
JournalWorld Neurosurg
Volume116
Pagination518-528
Date Published2018 Aug
ISSN1878-8769
KeywordsAntibodies, Monoclonal, Combined Modality Therapy, Dendritic Cells, Glioblastoma, Humans, Immunotherapy, T-Lymphocytes
Abstract

Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor vaccinations from both dendritic cell and tumor peptide components, adoptive transfer of supercharged and durable T lymphocytes, and generation of oncolytic viruses. Although immunotherapy has already demonstrated efficacy for a variety of other malignancies, its efficacy in glioblastoma is still unclear. Identifying predictive biomarkers and improving the management of immune-related adverse effects will help to realize the full potential of these therapies.

DOI10.1016/j.wneu.2018.04.020
Alternate JournalWorld Neurosurg
PubMed ID30049046

Weill Cornell Medicine Neurology 525 E. 68th St.
PO Box 117
New York, NY 10065 Phone: (212) 746-6575